[ Price : $8.95]
FDA clears a SimBioSys 510(k) for TumorSight Viz to expand its use by breast surgeons through artificial intelligence-based image ...[ Price : $8.95]
FDA extends by three months its priority review of a Merus BLA for Zeno (zenocutuzumab) for treating patients with certain types o...[ Price : $8.95]
Four rare disease stakeholders say they support an FDA plan to create a Rare Disease Innovation Hub and suggest its initial priori...[ Price : $8.95]
Attorney Bradley Thompson says he is surprised and disappointed that FDA is not approving enough new consensus standards to suppor...[ Price : $8.95]
FDA announces a pilot program designed to expedite the review of new therapies addressing unmet medical needs.[ Price : $8.95]
FDA removes the clinical holds on three CARsgen Therapeutics clinical trials evaluating CT053, CT041, and CT071.[ Price : $8.95]
FDA agrees on a Phase 3 study design for Disc Medicines bitopertin and its use in treating a rare sunlight sensitivity disorder.[ Price : $8.95]
FDA clears a Quanta Dialysis Technologies 510(k) for the use of its Quanta Dialysis System in the home setting.